STOCK TITAN

Exact Sciences Corp - EXAS STOCK NEWS

Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.

Exact Sciences Corp (symbol: EXAS) is a leading molecular diagnostics company based in Madison, Wisconsin. The company specializes in providing innovative cancer screening and diagnostic test products, both in the United States and internationally. One of the company's flagship products is Cologuard, a groundbreaking noninvasive stool-based DNA test that screens for colorectal cancer. This test is integrated into the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.

Exact Sciences is also making significant strides in the field of precision oncology. Their Oncotype DX suite includes tissue-based genomic tests that help estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy for breast and colon cancer patients. Additionally, the OncoExTra test offers comprehensive genomic profiling through a liquid biopsy, providing valuable insights for personalized cancer treatment.

In addition to these established products, Exact Sciences is actively developing new liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. These ongoing projects reflect the company's commitment to advancing cancer diagnostics and improving patient outcomes.

The company's intellectual property portfolio is robust, with exclusive rights protecting its proprietary non-invasive molecular screening technology. This strong IP position underscores Exact Sciences' leadership and innovation in the cancer diagnostics market.

  • Headquartered in Madison, Wisconsin
  • Specializes in cancer screening and diagnostic tests
  • Flagship product: Cologuard, a noninvasive colorectal cancer screening test
  • Precision oncology products: Oncotype DX and OncoExTra
  • Active development of liquid biopsy tests
  • Exclusive intellectual property rights protecting screening technology

For more information on Exact Sciences' noninvasive colon cancer screening test, visit cologuardtest.com.

Rhea-AI Summary
Exact Sciences Corp. announces late-breaking data from the BLUE-C trial showing the next-generation Cologuard test met all study endpoints, demonstrating 94% sensitivity for colorectal cancer at 91% specificity. Results show next-generation Cologuard test superior to FIT in sensitivity for colorectal cancer and pre-cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. to present new data on early cancer detection and genomic testing at ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. to release Q3 2023 financial results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
Rhea-AI Summary
Exact Sciences Corp. to present late-breaking data on next-generation Cologuard at the ACG Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
conferences
-
Rhea-AI Summary
Exact Sciences acquires Resolution Bioscience to enhance cancer treatment solutions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. to participate in Baird Global Healthcare Conference on September 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
conferences
Rhea-AI Summary
Exact Sciences Corp. selected for ComboMATCH clinical trials to analyze tumor samples using OncoExTra test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
-
Rhea-AI Summary
New research reveals barriers to colorectal cancer screening among 45-year-olds in the US
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. reports record results for the second quarter of 2023, with total revenue of $622 million, an increase of 19%. The company also generated positive free cash flow of $66 million and raised its full-year revenue and adjusted EBITDA guidance. Exact Sciences anticipates revenue of $2.441-$2.466 billion for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.73%
Tags
Rhea-AI Summary
Exact Sciences Corp. plans to release its second quarter 2023 financial results on August 1, 2023. The company will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags

FAQ

What is the current stock price of Exact Sciences (EXAS)?

The current stock price of Exact Sciences (EXAS) is $49.54 as of November 18, 2024.

What is the market cap of Exact Sciences (EXAS)?

The market cap of Exact Sciences (EXAS) is approximately 9.2B.

What is Exact Sciences Corp's main business?

Exact Sciences Corp specializes in molecular diagnostics, focusing on innovative cancer screening and diagnostic test products.

What is Cologuard?

Cologuard is a noninvasive stool-based DNA test designed to screen for colorectal cancer, integrated into major colorectal cancer screening guidelines.

Where is Exact Sciences Corp headquartered?

The company is headquartered in Madison, Wisconsin.

What are Oncotype DX and OncoExTra?

Oncotype DX is a suite of tissue-based genomic tests for cancer recurrence risk and chemotherapy benefit; OncoExTra is a liquid biopsy for comprehensive genomic profiling.

Is Exact Sciences developing any new tests?

Yes, the company is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

What is the significance of Exact Sciences' intellectual property?

Exact Sciences has exclusive intellectual property rights protecting its noninvasive molecular screening technology, reinforcing its market leadership.

Are Exact Sciences' products used internationally?

Yes, Exact Sciences provides cancer screening and diagnostic test products both in the United States and internationally.

How does Cologuard work?

Cologuard works by analyzing stool samples for DNA markers and blood that could indicate the presence of colorectal cancer or precancerous lesions.

What is the purpose of Oncotype DX tests?

Oncotype DX tests aim to estimate the risk of cancer recurrence and the likelihood of benefit from chemotherapy in breast and colon cancer patients.

Where can more information about Cologuard be found?

More information about Cologuard can be found at cologuardtest.com.

Exact Sciences Corp

Nasdaq:EXAS

EXAS Rankings

EXAS Stock Data

9.16B
185.08M
1%
99.1%
8.41%
Diagnostics & Research
Services-medical Laboratories
Link
United States of America
MADISON